Lexeo Therapeutics, Inc. - Common Stock (LXEO)

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Lexeo reported strong interim results for LX2006 in ataxia cardiomyopathy, with plans to start a registrational study by early 2026.

Two biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value.

The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.